- Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies2021 | 2. lékařská fakulta
- Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study2023 | 1. lékařská fakulta, Lékařská fakulta v Plzni
- Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group2022 | 2. lékařská fakulta
- Management of patients with intermediate-risk early stage cervical cancer2020 | 1. lékařská fakulta
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease2016 | Publikace bez příslušnosti k fakultě
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease2016 | Publikace bez příslušnosti k fakultě
- Early-stage intermediate-risk-the group with the most heterogenous management among patients with cervical cancer2022 | 1. lékařská fakulta
- Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes2021 | 3. lékařská fakulta, Ústřední knihovna
- Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission2018 | 3. lékařská fakulta, Lékařská fakulta v Hradci Králové
- 5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer-A Retrospective Analysis2023 | 1. lékařská fakulta
- PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer2020 | 1. lékařská fakulta
- Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial2007 | 2. lékařská fakulta
- Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease2021 | Publikace bez příslušnosti k fakultě
- Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke2019 | 3. lékařská fakulta
- CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)2022 | 1. lékařská fakulta, Filozofická fakulta
- Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature2018 | 1. lékařská fakulta
- Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients2020 | 1. lékařská fakulta, Lékařská fakulta v Plzni
- Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group2013 | 2. lékařská fakulta
- A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial)2020 | 1. lékařská fakulta
- Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results2013 | 1. lékařská fakulta, 2. lékařská fakulta
- Multi-parametric functional hemodynamic optimization improves postsurgical outcome after intermediate risk open gastrointestinal surgery, a randomized controlled trial2019 | Lékařská fakulta v Plzni
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Lékařská fakulta v Plzni
- MINIMALLY INVASIVE PELVIC LYMPHADENECTOMY DURING RADICAL PROSTATECTOMY - SINGLE SURGEON TECHNIQUE EVOLUTION IN MULTICENTER SETTINGPublikace bez příslušnosti k fakultě
- Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?2018 | 1. lékařská fakulta, 2. lékařská fakulta
- De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors2024 | Lékařská fakulta v Hradci Králové, Lékařská fakulta v Plzni, Ústřední knihovna
- Zpráva FNHK ke klinickému hodnocení č. protokolu: 20090160-21010Publikace bez příslušnosti k fakultě
- Multicentrická , randomizovaná , otevřená studie fáze III decitabin versus léčba na přání pacienta s poradenstvím lékaře, buď s podpůrnou péčí nebo nízkou dávkou cytarabinu u léčby starších pacientů s nově diagnostikovanou akutní myeloidní leukémií2012 | 1. lékařská fakulta
- Radioterapie v léčbě epiteliálního karcinomu ovarií2003 | 1. lékařská fakulta
- Transcatheter aortic valve implantation in patient with cardiogenic shock2018 | Publikace bez příslušnosti k fakultě
- Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study2015 | 1. lékařská fakulta